An index of frontier and emerging AI labs.
Bio / AI drug discovery
AI-native biologics lab designing antibodies and bispecifics. Closed $787M in March 2026 financing (Dimension Capital, DST Global, INCE, Luminous, Sanofi, Hillhouse-Pfizer Biotech Development Fund). Sanofi TL1A bispecifics partnership worth up to $2.56B in milestones.
| Name | Earendil Labs |
|---|---|
| Space | Bio / AI drug discovery |
| Founded | 2023 |
| Latest valuation | ~$1B |
| Stage | — |
| Status | active |
| HQ | Wilmington, DE |
| Founders | Bo Chen |
| Website | https://earendil.bio |
| Careers | — |
| — | |
| X / Twitter | — |
| Date | Round | Amount ($M) | Valuation | Confidence | Source |
|---|---|---|---|---|---|
| — | — | — | ~$1B | reported | — |
No founders recorded yet. Submit info.
| Date | Type | Title | Source |
|---|---|---|---|
| 2026-06-14 | added | Earendil Labs added to tracker Latest valuation: ~$1B. | — |
No sources cited.
| Lab | Valuation | Founded |
|---|---|---|
| Isomorphic Labs | >$15B | 2021 |
| Xaira Therapeutics | ~$4B | 2024 |
| insitro | ~$2.5B | 2018 |
| Generate Biomedicines | ~$2B | 2018 |
| Recursion | ~$1.75B (mkt cap) | 2013 |
| Chai Discovery | $1.3B | 2024 |
| EvolutionaryScale | >$1B | 2024 |
| Genesis Therapeutics | ~$1B | 2019 |